Today's Medical & Research News
Myelodysplastic Syndrome
Research from Catholic University yields new data on myelodysplastic syndrome
May 7th, 2008
(NewsRx.com) -- "To asses the real contribution of pre-transplantation treatment in the incidence of secondary neoplasia after autologous transplant for lymphoproliferative disorders, we used stringent inclusion/exclusion criteria. One hundred and forty-two patients out of 323 that underwent autologous transplantation for lymphoproliferative disorders were studied," scientists writing in the journal Clinical Transplantation report. "The risk factors that were evaluated with univariate and multivariate analysis included: gender, sex, age, diagnosis, radiotherapy, and chemotherapy prior to conditioning regimen, disease status at peripheral blood stem-cell transplantation (PBSCT) and type of harvest. Three patients developed secondary myelodysplastic syndrome/acute myeloid leukemia (sMDS/AML) and three patients developed solid neoplasia. By univariate analysis diagnosis chronic lymphocytic leukemia and use of fludarabine and monoclonal antibodies were the only variables significantly associated with the development of sMDS/AML. By multivariate analysis, the variables associated with sMDS/AML were the use of fludarabine and disease status at PBSCT. By univariate analysis, we found that radiotherapy and the use of monoclonal antibodies were significantly associated with the development of secondary solid neoplasia. Multivariate analysis confirmed that the only two variables significantly associated with new cancers were radiotherapy and prior treatment with monoclonal antibodies. We report the lowest incidence of sMDS/AML after autologous stem-cell transplantation for lymphoproliferative malignancies. Major reasons could be ascribed to the stringent inclusion/exclusion criteria used to establish the real incidence of sMDS/AML because of chemo-radiotherapy used before transplant procedure," wrote L. Laurenti and colleagues, Catholic University. The researchers concluded: "The low incidence of secondary solid tumors could be caused by the absence of total body irradiation as part of the conditioning regimen or the short follow-up." Laurenti and colleagues published their study in Clinical Transplantation (Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. Clinical Transplantation, 2008;22(2):191-199). Additional information can be obtained by contacting L. Laurenti, Sacred Heart Catholic University, Dept. of Hematology, Division Ematol, Largo A Gemelli 8, I-00168 Rome, Italy. The publisher of the journal Clinical Transplantation can be contacted at: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England. Keywords: Italy, Rome, Acute Myeloid Leukemia, Antimetabolite, Antineoplastic, Autologous Transplant, Biotechnology, Blood Transfusion, Cell Transplantation, Chemotherapy, Chronic Lymphocytic Leukemia, Clinical Transplantation, Cord Blood, Drug Therapy, Fludarabine, Gender Health, Gender Medicine, Hematology, Immunosuppressant, Lymphoproliferative Disorder, Medical Device, Monoclonal Antibody, Myelodysplastic Syndromes, Neoplasia, Oncology, Stem Cell Research, Surgery, Transfusion Medicine, Treatment, Women's Health, Catholic University. This article was prepared by NewsRx editors from staff and other reports. Copyright 2008, NewsRx.com.
|
